Andros Pharmaceuticals Co (ROCO:6917) EV-to-EBIT : -7.72 (As of Jun. 05, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Andros Pharmaceuticals Co's Enterprise Value is NT$522.49 Mil. Andros Pharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-67.70 Mil. Therefore, Andros Pharmaceuticals Co's EV-to-EBIT for today is -7.72.

The historical rank and industry rank for Andros Pharmaceuticals Co's EV-to-EBIT or its related term are showing as below:

ROCO:6917' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.73 Med: -16.67 Max: -4.64
Current: -7.72

During the past 5 years, the highest EV-to-EBIT of Andros Pharmaceuticals Co was -4.64. The lowest was -25.73. And the median was -16.67.

ROCO:6917's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs ROCO:6917: -7.72

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Andros Pharmaceuticals Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$701.57 Mil. Andros Pharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-67.70 Mil. Andros Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9.65%.

Andros Pharmaceuticals Co EV-to-EBIT Historical Data

The historical data trend for Andros Pharmaceuticals Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co EV-to-EBIT Chart

Andros Pharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-10.36

Andros Pharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	-	-10.36

Competitive Comparison of Andros Pharmaceuticals Co's EV-to-EBIT

For the Biotechnology subindustry, Andros Pharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Andros Pharmaceuticals Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's EV-to-EBIT falls into.

Andros Pharmaceuticals Co EV-to-EBIT Calculation

Andros Pharmaceuticals Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	522.485	/	-67.697
	=	-7.72

Andros Pharmaceuticals Co's current Enterprise Value is NT$522.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Andros Pharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-67.70 Mil.

Andros Pharmaceuticals Co (ROCO:6917) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Andros Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-67.697	/	701.5734
	=	-9.65 %

Andros Pharmaceuticals Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$701.57 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Andros Pharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-67.70 Mil.

Andros Pharmaceuticals Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co (ROCO:6917) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261

Website

http://www.androspharma.com

Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co (ROCO:6917) Headlines

No Headlines